APOE and early-onset autosomal dominant Alzheimer disease: Our study revealed that Alzheimer’s disease patients carrying the APOE ε4 homozygous allele exhibited significantly higher ARIA-E incidence following lecanemab/donanemab treatment compared to non-carriers, with a relatively attenuated risk increase observed in the lecanemab group.